1 / 4

Strategic Importance of Portfolio Management in the Pharma and Healthcare Industry

R&D organizations are under pressure to contribute to increased efficiency in creating novel pharmaceuticals due to the escalating costs of pharmaceutical research. The pharmaceutical industry has worked incredibly hard in recent years to find solutions to these problems and boost the effectiveness of the medication development process.

xmichael
Télécharger la présentation

Strategic Importance of Portfolio Management in the Pharma and Healthcare Industry

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Strategic Importance of Portfolio Management in the Pharma and Healthcare Industry Portfolio Management In Healthcare R&D organizations are under pressure to contribute to increased efficiency in creating novel pharmaceuticals due to the escalating costs of pharmaceutical research. The pharmaceutical industry has worked incredibly hard in recent years to find solutions to these problems and boost the effectiveness of the medication development process. Unquestionably, some of the projects have yielded notable improvements. Early studies to ascertain if a novel drug candidate is suitable for oral delivery or once-daily dosing are two examples, as are early assessments of a drug's toxicological profile. It is now more important to consider if we are acting morally rather than how talented we are at what we do. Further improvements to the process should focus on

  2. how effective the procedures are rather than trying to increase efficacy. In this circumstance, portfolio management is severely stressed. What is Portfolio Management? In its broadest sense, portfolio management refers to the process of maximizing the value of R&D portfolios through effective resource allocation, whereas Strategic Portfolio Management (SPM) refers to a set of business practices and competencies to identify the best investments to be made to realize the overall strategy of the organization. As part of the value-driven project and portfolio management, individual projects and portfolios are exposed to quantitative finance and risk analysis. These evaluations offer several ways to raise the value and risk structure of specific projects, therapeutic areas, and complete corporate portfolios, on the one hand, and of therapeutic areas or comprehensive corporate portfolios, on the other. A pharmaceutical R&D portfolio is often created by combining different assets. It may include medical devices, small molecules, and biologics (Phase I–IV) at the discovery, preclinical, and development stages. Less experienced biotech companies are more likely only to have one platform or project under their control and no sizable R&D portfolio to oversee. Large pharmaceutical and biotech corporations actively manage their project portfolios, which include a variety of initiatives at various stages of development. The most important variables in establishing the company's overall shareholder value are portfolio decisions, such as medicine candidate selection, portfolio prioritization, and optimization. Portfolio Management by Stages Evaluation Both R&D and commercial teams offer services related to development, manufacturing, commercial expenses, clinical risk-benefit analysis, intellectual property (IP), and competitive landscape analysis. The portfolio team generates outputs for senior leadership to employ in decision-making, such as business valuations and associated metrics. Prioritization Prioritizing projects based on their scientific and commercial merits, as well as any associated risk and uncertainty, is how project portfolio management is accomplished. The development of the agent with the greatest likelihood of success ought to be given top priority. The most significant initiatives shouldn't have any resource restrictions (budget and FTEs). Optimization Pharmaceutical companies choose and progress their assets from drug discovery to preclinical testing and ultimately development using certain selection criteria. The best portfolios contain a wide range of early-stage prospects and backup agents that may be helpful if the lead

  3. compound's development is halted. Risk assessment is a crucial component of portfolio management and development decisions in any circumstance. Benefits of Strategic Portfolio Management in Pharmaceutical Companies ● ● ● ● Transparency Strategic Alignment Understanding The Potential Even Distribution and Valuation Conclusion Corporate strategy determines the drug development pipeline, and a company's pharmaceutical portfolio comprises specific projects in various phases of development. An effective medication portfolio management approach and an optimized portfolio strategy are the essential elements and enablers of every pharmaceutical company's commercial success. It is suggested that the industry employ contemporary decision-making processes and organized portfolio management to reduce choice bias and investment hazards. The most crucial elements in defining the company's overall shareholder value are portfolio decisions, such as medicine candidate selection, portfolio prioritization, and optimization. The research and development portfolio needs to be evaluated concerning costs, clinical risk-benefit, intellectual property, peak sales, profit, and other elements to advance. Prioritization of projects aids in determining their risks and likelihood of success, while optimization ensures that only the most promising compounds reach the clinical stage by strategically choosing whether to license or discontinue the product in the middle of development. In conclusion, transparent decision-making, strategic alignment, options, and emotional value are all provided by strategic portfolio management. Pharmaceutical strategic portfolio management is anticipated to become more significant given the high stakes of drug discovery and how well it lends itself to portfolio management methodologies. Related Reports: Diagnostic Imaging Equipment Market Diagnostic Imaging Equipment Market By Product (X-Ray Imaging Systems, Computed Tomography (CT) Scanners, Ultrasound Systems, Magnetic Resonance Imaging (MRI) Systems, Nuclear Imaging Systems, Mammography Systems, And Others), By Application (Cardiology, Oncology, Gastroenterology, Gynecology, And Other Applications), By End-User (Hospitals, Diagnostic Imaging Centres, And Others), by geography is expected to grow at a steady CAGR forecast till 2026 owing to rising technological advancement and increasing prevalence of chronic diseases.

  4. Invasive Candidiasis Market "DelveInsight’s ‘Invasive Candidiasis Market Insight, Competitive Landscape and Market Forecast, 2027’ report delivers an in-depth understanding of Invasive Candidiasis and the historical and forecasted Invasive Candidiasis market trends, globally, which comprises of North America, Europe, APAC, and RoW. Sialidosis Market DelveInsight's "Sialidosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Sialidosis, historical and forecasted epidemiology as well as the Sialidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Filgrastim Biosimilar Insight DelveInsight’s, “Filgrastim Biosimilar Insight, 2022,” report provides comprehensive insights about 20+ companies and 20+ marketed and pipeline drugs in the Filgrastim Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Pain Management Devices Market Pain Management Devices Market By Type Of Devices (Neuromodulation & Neurostimulation Devices, Analgesic Infusion Pumps [Intrathecal Infusion Pumps and External Infusion Pumps], Ablation Devices [Radiofrequency Ablation Devices And Cryoablation Devices], And Others), By Application (Neuropathic Pain, Cancer Pain, Facial & Migraine Pain, Musculoskeletal Pain, and Others), By Geography is expected to grow at a steady CAGR Forecast till 2027 Latest Reports by DelveInsight Basal Cell Carcinoma Market | Birch Allergy Market | Bile Duct Neoplasm Market | Gingivitis Market | Lupus Nephritis Market | Severe Hypertriglyceridemia (SHTG) Market | Arthralgia Market | Severe Hypertriglyceridemia (SHTG) Market | Arthralgia Market | Congestive Heart Failure Market | Gingivitis Market | Lupus Nephritis Market | Erythromelalgia Market | AL Amyloidosis Market | Primordial Dwarfism Market | Breast Pumps Market | Hyperuricemia Market | Helicobacter Pylori (H. pylori) Infection Market | AIDS Dementia- Market | Follicular Lymphoma Market | Chronic Pulmonary Hypertension Market | Adrenal Crisis Market | Retinoblastoma Market | Non-Cystic Fibrosis Bronchiectasis Market | Microsatellite Stable Colorectal Cancer Market | Chondrosarcoma Market | Sialidosis Market To know more about our Competitive Services, Click here: Pharma Competitive Intelligence https://www.delveinsight.com/consulting/competitive-intelligence-services

More Related